Pre-onlines

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: Implications for optimized treatment

John K Cowell, Tianxiang Hu

DOI: 10.20517/cdr.2021.30 24 May 2021

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Haiyun Zhang, Alexander Steed, Milo Co, Xiaozhuo Chen

DOI: 10.20517/cdr.2021.32 16 Jun 2021

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Robert Clarke, Brandon C. Jones, Catherine M. Sevigny, Leena A. Hilakivi-Clarke, Surojeet Sengupta

DOI: 10.20517/cdr.2021.33 7 Jul 2021

Drug resistance in targeted cancer therapies with RAF inhibitors

Ufuk Degirmenci, Jiajun Yap, Yuen Rong M. Sim, Shiru Qin, Jiancheng Hu

DOI: 10.20517/cdr.2021.36 16 Jun 2021

Advances in preclinical evaluation of experimental antibody drug conjugates

Scott K. Lyons, Dennis Plenker, Lloyd C. Trotman

DOI: 10.20517/cdr.2021.37 3 Jul 2021

Notch signaling in female cancers: a multifaceted node to overcome drug resistance

Maria V. Giuli, Angelica Mancusi, Eugenia Giuliani, Isabella Screpanti, Saula Checquolo

DOI: 10.20517/cdr.2021.53 5 Aug 2021

MYC inhibitors in multiple myeloma

Sandra Martínez-Martín, Laura Soucek

DOI: 10.20517/cdr.2021.55 12 Aug 2021

The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres

Seung-Hun Kim, Po-Wei Fan, Chang-Heng Hsieh, Hsuan-Yuan Lin, Wen-Hsin Wang, Ming-Chung Lee, Kang Fang

DOI: 10.20517/cdr.2021.58 12 Aug 2021

Tackling cisplatin resistance in ovarian cancer: what can we do?

Paola Perego

DOI: 10.20517/cdr.2021.59 7 Jul 2021

Targeting DNA topoisomerases: past & future

William H. Gmeiner, Robert C. A. M. van Waardenburg

DOI: 10.20517/cdr.2021.65 20 Jul 2021

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

Fuyuhiko Motoi

DOI: 10.20517/cdr.2021.75 7 Sep 2021

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: Implications for optimized treatment

DOI: 10.20517/cdr.2021.30

John K Cowell, Tianxiang Hu

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

DOI: 10.20517/cdr.2021.32

Haiyun Zhang, Alexander Steed, Milo Co, Xiaozhuo Chen

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

DOI: 10.20517/cdr.2021.33

Robert Clarke, Brandon C. Jones, Catherine M. Sevigny, Leena A. Hilakivi-Clarke, Surojeet Sengupta

Drug resistance in targeted cancer therapies with RAF inhibitors

DOI: 10.20517/cdr.2021.36

Ufuk Degirmenci, Jiajun Yap, Yuen Rong M. Sim, Shiru Qin, Jiancheng Hu

Advances in preclinical evaluation of experimental antibody drug conjugates

DOI: 10.20517/cdr.2021.37

Scott K. Lyons, Dennis Plenker, Lloyd C. Trotman

Notch signaling in female cancers: a multifaceted node to overcome drug resistance

DOI: 10.20517/cdr.2021.53

Maria V. Giuli, Angelica Mancusi, Eugenia Giuliani, Isabella Screpanti, Saula Checquolo

MYC inhibitors in multiple myeloma

DOI: 10.20517/cdr.2021.55

Sandra Martínez-Martín, Laura Soucek

The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres

DOI: 10.20517/cdr.2021.58

Seung-Hun Kim, Po-Wei Fan, Chang-Heng Hsieh, Hsuan-Yuan Lin, Wen-Hsin Wang, Ming-Chung Lee, Kang Fang

Tackling cisplatin resistance in ovarian cancer: what can we do?

DOI: 10.20517/cdr.2021.59

Paola Perego

Targeting DNA topoisomerases: past & future

DOI: 10.20517/cdr.2021.65

William H. Gmeiner, Robert C. A. M. van Waardenburg

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

DOI: 10.20517/cdr.2021.75

Fuyuhiko Motoi

Pre-onlines

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: Implications for optimized treatment

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Drug resistance in targeted cancer therapies with RAF inhibitors

Advances in preclinical evaluation of experimental antibody drug conjugates

Notch signaling in female cancers: a multifaceted node to overcome drug resistance

MYC inhibitors in multiple myeloma

The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres

Tackling cisplatin resistance in ovarian cancer: what can we do?

Targeting DNA topoisomerases: past & future

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico